A comprehensive study of clinical and molecular features in patients with metastatic colorectal cancer with and without liver mets. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...
Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer. Findings from a recent clinical trial ...
FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...
Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with so-called “HER2-ultralow” status. The company’s PATHWAY HER2 antibody test ...
Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...
The PATHWAY HER2 (4B5) test helps to identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA.
A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...
Mammary epithelial cells grow in clusters called acini. When HER2 signaling is activated, the clusters -- which normally have hollow centers -- assume an irregular, or dysplastic form (left). When ...
Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in order to keep resources flowing toward its leukemia candidate. The ...
TUCSON, Ariz., Nov. 25, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback